Sector footprint
$9.1M in exports
Reported chemicals exports in 2024 across 20 qualifying HS6 products.
Sector export playbook ยท HS 28-38
Explore Mauritius's HS 28-38 product portfolio, buyer markets, growth signals, and diversification opportunities. Use this guide to prioritize research, not to treat calculated indicators as guaranteed sales.
Chemicals capability
Compare exporter scale with product breadth, buyer demand, growth, and destination reach. A large sector does not remove the need for product, compliance, pricing, and buyer validation.
Sector footprint
Reported chemicals exports in 2024 across 20 qualifying HS6 products.
Global demand
The sector's reported buyer import base provides context for product and market prioritization.
How to use the guide
Start with products that combine demand and exporter capability, then validate standards, route economics, buyers, and competition.
Product portfolio
Each HS6 product is ranked by calculated opportunity and shown with reported market size, exporter exports, growth, and destination reach.
| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
|---|---|---|---|---|---|---|
| HS 300490Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $288.6B | $1.7M | $102.1B | +0.7% | 20 | +0.0% |
| HS 382499Chemical products, mixtures and preparations: n.e.c. heading 3824 | $23.6B | $26.6K | $13.5B | +22.3% | 8 | +0.0% |
| HS 300212Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $24.4B | $1.9M | $12.8B | +104.6% | 5 | +0.0% |
| HS 330499Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $25.4B | $709.7K | $10.9B | +11.8% | 8 | +0.0% |
| HS 300215Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $28.4B | $1.1M | $10.5B | +216.6% | 3 | +0.0% |
| HS 382200Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $19.7B | $6.8K | $8.8B | -4.1% | 6 | +0.0% |
| HS 330300Perfumes and toilet waters | $11.9B | $2.9M | $7.2B | +13.4% | 6 | +0.0% |
| HS 330210Odoriferous substances and mixtures: of a kind used in the food or drink industries | $5.4B | $83.9K | $6.7B | +1.3% | 2 | +0.0% |
| HS 300439Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $5.1B | $106.1K | $4.2B | +16.3% | 2 | +0.0% |
| HS 300290Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $4.9B | $419.1K | $2.5B | +19.7% | 3 | +0.0% |
| HS 293299Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $9.7K | $2.0B | -31.1% | 1 | +0.0% |
| HS 370790Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $1.9K | $1.8B | -3.5% | 1 | +0.0% |
| HS 381800Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $3.7B | $32.9K | $1.5B | -11.2% | 2 | +0.0% |
| HS 300390Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $484.8 | $1.2B | -5.9% | 1 | +0.0% |
| HS 300220Vaccines: for human medicine | $1.4B | $86.6K | $1.2B | +77.9% | 1 | +0.0% |
| HS 321590Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $471.7 | $1.1B | +19.2% | 1 | +0.0% |
| HS 294190Antibiotics: n.e.c. in heading no. 2941 | $883.6M | $7.9 | $990.0M | -20.7% | 1 | +0.0% |
| HS 330290Odoriferous substances and mixtures: used as raw materials in industries other than the food or drink industries | $1.3B | $119.8 | $803.3M | -9.7% | 1 | +0.0% |
| HS 281820Aluminium oxide: other than artificial corundum | $1.0B | $17.8K | $764.1M | +2.1% | 1 | +0.0% |
| HS 340600Candles, tapers and the like | $1.0B | $185.0 | $640.9M | -29.2% | 1 | +0.0% |
Best markets
Markets are ranked by calculated opportunity across the qualifying products in this sector view.
USA
12 products represented in the sector.
$45.7B$123.3B reported buyer importsCHE
4 products represented in the sector.
$36.6B$57.2B reported buyer importsCHN
6 products represented in the sector.
$16.0B$37.4B reported buyer importsDEU
7 products represented in the sector.
$13.6B$46.8B reported buyer importsFRA
8 products represented in the sector.
$11.6B$28.5B reported buyer importsNLD
2 products represented in the sector.
$10.5B$24.1B reported buyer importsESP
4 products represented in the sector.
$8.1B$16.0B reported buyer importsBEL
2 products represented in the sector.
$7.9B$20.3B reported buyer importsCAN
4 products represented in the sector.
$6.9B$11.5B reported buyer importsGBR
4 products represented in the sector.
$6.4B$17.7B reported buyer importsITA
1 products represented in the sector.
$4.9B$14.7B reported buyer importsJPN
2 products represented in the sector.
$4.4B$13.1B reported buyer importsGrowth stars
Average product-level CAGR is a screening signal. Confirm the latest trend, base effects, buyer quality, and commercial feasibility before acting.
| Product | Average CAGR | Opportunity | Markets |
|---|---|---|---|
| HS 300215Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | +216.6% | $10.5B | 3 |
| HS 300212Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | +104.6% | $12.8B | 5 |
| HS 300220Vaccines: for human medicine | +77.9% | $1.2B | 1 |
| HS 382499Chemical products, mixtures and preparations: n.e.c. heading 3824 | +22.3% | $13.5B | 8 |
| HS 300290Toxins, cultures of micro-organisms (excluding yeasts) and similar products | +19.7% | $2.5B | 3 |
| HS 321590Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | +19.2% | $1.1B | 1 |
| HS 300439Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | +16.3% | $4.2B | 2 |
| HS 330300Perfumes and toilet waters | +13.4% | $7.2B | 6 |
| HS 330499Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | +11.8% | $10.9B | 8 |
| HS 281820Aluminium oxide: other than artificial corundum | +2.1% | $764.1M | 1 |
Diversification opportunities
Destination count is a simple breadth indicator. It does not measure destination concentration or guarantee resilience.
HS 300490
HS 382499
HS 330499
HS 382200
HS 330300
HS 300212
HS 300215
HS 300290
Frequently asked questions
Practical guidance for interpreting sector scale, growth, product breadth, and buyer markets.
Compare sector exports, product breadth, buyer markets, growth, and global demand. These signals identify research priorities rather than guarantee market access.
Products with higher average reported growth in the screened rows. Validate the time period, base effects, buyer demand, and current exporter position.
Products reaching more buyer markets in the screened data. Destination breadth is useful context but does not replace concentration, route, or buyer analysis.
Data source
OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). OECD BIMTS is the primary trade series for this view. Supporting bilateral trade context uses CEPII BACI bilateral trade flows (202601) under Etalab 2.0 Open Licence. Yugalinks presents derived views of reported observations and calculated indicators. Data terms: OECD Terms & Conditions.